Muhammad Ali Haider, et al
and 6 months post treatment would not be significantly
different from baseline values at the start of
treatment19. Thus, based on these results early
treatment of macular edema is indicated for better and
sustained anatomical and visual results. Thus earlier
detection of reduced visual acuity is significantly
important for the treatment of recurring macular
edema. Another study highlighted the correlation
between central subfield thickness and baseline visual
acuity after treatment with Bevacizumab20.
1. Bahrami B, Hong T, Gilles MC, Chang A. Anti-
VEGF Therapy for Diabetic Eye Diseases. Asia Pac J
2. Lam DS, Lai TY, Lee VY, Chan CK, Liu DT,
Mohamed S, et al. Efficacy of 1.25 MG versus 2.5 MG
intravitreal bevacizumab for diabetic macular edema:
six-month results of a randomized controlled trial.
Retina. 2009; 29 (3): 292-9.
3. Keane PA, Liakopoulos S, Chang KT, Wang M,
Dustin L, Walsh AC, et al. Relationship between
optical coherence tomography retinal parameters and
visual acuity in neovascular age-related macular
degeneration. Ophthalmology, 2008; 115 (12): 2206-
4. Yang J, Wang X, Fuh G, Yu L, Wakshull E,
Khosraviani M, et al. Comparison of binding
characteristics and in vitro activities of three inhibitors
of vascular endothelial growth factor A. Mol Pharm.
2014; 11 (10): 3421-30.
Consistent with other studies, younger age of
patients with diabetic macular edema was associated
with significantly improved visual acuitys and reduced
central retinal thickness after every 6 weeks of
treatment. However, if the treatment is delayed by
6 weeks, repetition of intravitreal
bevacizumab would not result in significant visual
Limitation of our study was the small sample size.
We did not study the association of vascular patterns
of macula on OCTA with decreased visual acuity,
which is also a contributory factor in decreased visual
5. Demirel S, Argo C, Agarwal A, Parriott J, Sepah
YJ, Do DV, et al. Updates on the Clinical Trials in
Diabetic Macular Edema. Middle East Afr
Ophthalmol. 2016; 23 (1): 3-12.
6. Pescosolido N, Pranno F, Buomprisco G. Intravitreal
injections and diabetic macular edema: actual and new
therapeutic options. Curr Diabetes Rev. 2013; 9 (6):
7. Vyas S, Thapa R, Bajimaya S, Pradhan E, Paudyal
G. Anatomical and visual outcome of intravitreal
bevacizumab (Avastin) in patients with diabetic
macular edema. Nepal J Ophthalmol. 2016; 8 (15): 54-
8. Das T, Aurora A, Chhablani J, Giridhar A, Kumar
A, Raman R, et al. Evidence-based review of diabetic
macular edema management: Consensus statement on
Indian treatment guidelines. Indian J Ophthalmol. 2016;
64 (1): 14-25.
9. Sala-Puigdollers A, Figueras-Roca M, Hereu M,
Hernandez T, Morato M, Adan A, et al. Repeatability
and reproducibility of retinal and choroidal thickness
measurements in Diabetic Macular Edema using Swept-
source Optical Coherence Tomography. PloS one,
2018; 13 (7): e0200819.
Thus based on our study results, 45µm reduction in
central macular thickness is associated with 0.1
LogMAR unit improvement in visual acuity in patients
with Diabetic Macular edema after a single dose of
Intravitreal Bevacizumab (1.25 mg).
The study was approved by the Institutional review
board/Ethical review board.
Conflict of Interest
Authors declared no conflict of interest.
10. Browning DJ, Glassman AR, Aiello LP, Beck RW,
Brown DM, et al. Diabetic Retinopathy Clinical
Research Network. Relationship between optical
coherence tomography-measured central retinal
thickness and visual acuity in diabetic macular edema.
Ophthalmology, 2007; 114 (3): 525-36.
Author’s Designation and Contribution
Muhammad Ali Haider; Assistant Professor: Study
Design, Data collection, Manuscript writing, and
11. Bhende M, Shetty S, Parthasarathy MK, Ramya S.
Uzma Sattar; Optometrist: Compiling Results, Data
Analysis, Article review.
Optical coherence tomography:
interpretation of common macular diseases. Indian J
Ophthalmol. 2018; 66 (1): 20-35.
Pakistan Journal of Ophthalmology, 2020, Vol. 36 (3): 292-297